This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration … directed to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, … include, but are not limited to, statements regarding our Axiomer® technology and our participation at this conference. …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
… ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event Initial … during which the Company will showcase its proprietary Axiomer RNA-editing technology platform, detail the pipeline, …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and … is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called …
… ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and … is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called …
